南新制药：以全维产品矩阵发力流感防控

Core Viewpoint - The company, Nanxin Pharmaceutical, is leveraging its technological advantages in the field of cold and antiviral drugs to ensure the production and supply of related treatment medications amid rising influenza virus activity levels in China [1][2]. Group 1: Product Portfolio and Innovation - Nanxin Pharmaceutical has established a comprehensive product matrix for influenza prevention and treatment, covering injectable and oral forms, as well as therapies for viral and bacterial infections, and antipyretic analgesics [1]. - The company's Palivizumab Sodium Injection is a representative of neuraminidase inhibitors, recognized as a core choice for influenza treatment in the latest national guidelines [1]. - The company is currently in the III phase of clinical trials for an inhalation solution of Palivizumab, which utilizes nebulization for direct action on the respiratory tract, enhancing patient compliance and offering a new option for influenza treatment [2]. Group 2: Targeted Treatments for Specific Populations - The company has developed a formulation of Oseltamivir Phosphate suitable for young children and elderly patients, addressing the need for appropriate dosage forms in these demographics [1]. - Nanxin Pharmaceutical offers a range of supportive treatments for influenza symptoms, including exclusive products like Compound Ibuprofen Tablets and formulations specifically designed for children, which have become common choices in pediatric care [2]. Group 3: Future Outlook and Commitment - The company aims to continuously optimize its product structure and provide efficient solutions for the prevention and treatment of influenza and other respiratory diseases, demonstrating its commitment to public health [2].